The trajectory of Sildenafil presents a intricate picture for shareholders. While the initial introduction generated substantial gains, the lapse of its patent opened the door to cheaper competitors, dramatically reducing sales. This presents a unique risk for pharmaceutical companies depending on related blockbuster medications, suggesting that a

The story of Viagra, and its parent company copyright, presents a complex case study for investors. Originally a blockbuster drug, producing billions in revenue , its exclusivity period created a deluge of lower-priced alternatives , significantly diminishing its market share . While some firms may attempt to capitalize on related treatments , the